Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Beroe introduces on-demand geopolitical risk analysis through PRISM enabling C-Suite to protect against ongoing supply chain disruptions




Blending a macro view of global risks with detailed category-specific procurement intelligence to enable fast, informed procurement decisions 

RALEIGH, N.C. and NEW YORK, March 6, 2024 /PRNewswire/ — Beroe, the provider of a SaaS procurement intelligence and analytics platform used by over 80% of Fortune 500 companies, today announced a strategic partnership with PRISM, the global geopolitical and macro risk advisory service. Through this partnership, Beroe’s customers will benefit from integrated alerts, reports and insights generated by PRISM’s political risk experts into Beroe LiVE.Ai, its AI-Powered Procurement Intelligence Platform.

With current and increasing geopolitical uncertainty, it is crucial for businesses operating global supply chains to know what is happening on a day-to-day basis and how these factors may impact their business, and what this means for their procurement operations. 

The 360-degree view of geopolitical and economic factors from PRISM allows Chief Procurement Officers (CPOs), Chief Finance Officers (CFOs) and other C-Suite leaders and their teams to proactively identify and prepare for supply chain risks and disruptions before these impact their business.

All Beroe LiVE.Ai users will immediately have access to top-level PRISM insights, with additional in-depth analysis available for an additional charge. Customers will benefit from forward-looking push alerts as well as visibility of industry implications and impact simulations available at the fingertips. 

Beroe provides highly granular AI-powered data and intelligence that helps inform and enable procurement decisions across industry sectors for a wide range of global players. Beroe LiVE.Ai is an AI-powered Procurement Intelligence Platform that surfaces immediate detailed insights to users. The Beroe LiVE.Ai engine also integrates with leading Source-to-Pay, contracting software solutions and enterprise messaging solutions. 

“Over the past few years, we have witnessed a large number of highly disruptive worldwide events, unparalleled in the modern era not only for their scale but also the impact on global businesses,” said Valekumar Krishnan, Chief Content Officer at Beroe Inc. “While procurement teams have had to react today to risks and disruption to international supply chains, CPOs are having to make strategic decisions for tomorrow against a backdrop of near-constant flux. Access to timely, accurate and insightful intelligence is critical to successfully plan and build a resilient supply chain. By integrating PRISM’s research and analysis into our AI-powered procurement intelligence platform we are supporting our customers with access to the most comprehensive suite of the best possible data and insights with which to run their businesses.” 

PRISM’s insights on global risks, including geopolitics, domestic politics, ESG, and economic shifts, complement Beroe’s existing data and information sources, providing actionable intelligence to help both C-Level and Procurement specialists to make strategic decisions around major world events likely to impact production, supply chain and distribution. PRISM provides tailored research, data, analysis, and expertise, helping senior executives and their teams make strategic decisions in high stakes environments. 

“Geopolitics and economic uncertainty are the biggest causes of risk to supply chains today. A solution for macro risk tracking is imperative for companies operating on a global scale to be ready for the next major disruption,” said Johan Gott, Co-founder of PRISM. “By integrating our intelligence-led and supply-chain focused macro expertise into Beroe’s market-leading solution we are providing Chief Procurement Officers and their teams of specialists with the full package of insights to help mitigate risk, manage suppliers and ultimately maximise business returns.” 

About Beroe 

Beroe, has been on procurement’s leading edge since the company’s founding in 2005, bringing a world of insights forward. The unique combination of Beroe’s expertise, artificial intelligence tools, and vast amounts of data, enable organizations to make smarter, faster, better procurement decisions. Not tomorrow, not today, but now. Beroe helps thousands of organizations sift through the data noise, mitigate risk, face fewer surprises, and ultimately gain a competitive edge. To learn more, please visit –

About PRISM 

PRISM is the world’s first macro risk advisory firm dedicated to tackling the geopolitical challenges facing supply chain and procurement leaders. PRISM provides research, analysis and expertise with a focus on simplifying the complexity of the global macro landscape to enable strategic decision-making.

By combining dedicated geopolitical and macro risk expertise with a global network of researchers and cutting-edge technology, PRISM’s services provide the most focused and tailored supply chain macro research available. 

Media Contact:
Rob McMurtrie
VP of Corporate Communications



Cision View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision,c3956826

The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895

EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading